{"id":1540,"date":"2026-11-04T08:33:56","date_gmt":"2026-11-04T08:33:56","guid":{"rendered":"https:\/\/admit-therapeutics.com\/?p=1540"},"modified":"2026-11-04T08:37:04","modified_gmt":"2026-11-04T08:37:04","slug":"admit-therapeutics-presenta-el-test-map-ad-en-el-del-xiii-congreso-argentino-de-la-calidad-en-el-laboratorio-clinico-calilab-2026","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-presenta-el-test-map-ad-en-el-del-xiii-congreso-argentino-de-la-calidad-en-el-laboratorio-clinico-calilab-2026\/","title":{"rendered":"ADmit Therapeutics presenta el test MAP-AD en el del XIII Congreso Argentino de la Calidad en el Laboratorio Cl\u00ednico (CALILAB 2026)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Barcelona, 4 de Noviembre de 2026. ADmit Therapeutics participar\u00e1 en la <strong>Jornadas de Neurogen\u00e9tica organizadas por MANLAB <\/strong>en el marco del <strong>XIII Congreso Argentino de la Calidad en el Laboratorio Cl\u00ednico (CALILAB 2026)<\/strong>. La Dra. Carla Trapero presentar\u00e1 el <strong>test MAP-AD<\/strong>, el \u00fanico test de pron\u00f3stico en sangre aprobado regulatoriamente (IVDR &#8211; EU 2017\/746) que predice la progresi\u00f3n a la demencia de Alzheimer en pacientes con deterioro cognitivo leve.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Para m\u00e1s informaci\u00f3n: <strong>https:\/\/diagnosticsnews.com\/especialidades-medicas\/jornadas-de-neurogenetica-manlab-marite-garimaldi-anticipa-los-avances-en-neurogenetica-y-alzheimer-que-manlab-presentara-en-calilab-2026<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Barcelona, 4 de Noviembre de 2026. ADmit Therapeutics participar\u00e1 en la Jornadas de Neurogen\u00e9tica organizadas por MANLAB en el marco del XIII Congreso Argentino de la Calidad en el Laboratorio Cl\u00ednico (CALILAB 2026). La Dra. Carla Trapero presentar\u00e1 el test MAP-AD, el \u00fanico test de pron\u00f3stico en sangre aprobado regulatoriamente (IVDR &#8211; EU 2017\/746) que [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-1540","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar-es"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/posts\/1540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=1540"}],"version-history":[{"count":1,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/posts\/1540\/revisions"}],"predecessor-version":[{"id":1541,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/posts\/1540\/revisions\/1541"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=1540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=1540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=1540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}